Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 28
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00688766 | Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib | ||
| NCT03719326 | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | ||
| NCT00724425 | A Phase 1 Dose Escalation Study of IPI-493 | ||
| NCT01228435 | IPI-504 in NSCLC Patients With ALK Translocations | ||
| NCT02028039 | IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | ||
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | ||
| NCT01310816 | A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma | ||
| NCT00761696 | A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies | ||
| NCT00969917 | Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma | ||
| NCT00113204 | Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma | ||
| NCT00817362 | Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | ||
| NCT01193491 | Dose Escalation of IPI-493 in Hematologic Malignancies | ||
| NCT00606814 | Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors | ||
| NCT01371617 | A Phase 2 Study With IPI-926 in Patients With Myelofibrosis | ||
| NCT00627419 | A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma | ||
| NCT03980041 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | ||
| NCT01362400 | A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer | ||
| NCT01871675 | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | ||
| NCT01130142 | A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer | ||
| NCT01427946 | Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer | ||
| NCT01383538 | FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma | ||
| NCT01609179 | IPI-926 Extension Protocol for Continuation of Treatment With IPI-926 | ||
| NCT00276302 | Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) | ||
| NCT03961698 | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma | ||
| NCT00564928 | A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer | ||
| NCT00431015 | Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) | ||
| NCT02598570 | Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma | ||
| NCT02640833 | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor |
